Bloating News and Research

RSS

Oxy-Powder supplement clears clinical trials for Irritable Bowel Syndrome

The popular nutraceutical health supplement, Oxy-Powder has passed clinical trials for Irritable Bowel Syndrome (IBS) with a 99.9 percent success rate.According to the NIH, approximately 20% of Americans suffer from the symptoms of IBS, which qualifies it as one of the most common medical problems in the United States.

21 Sep 2010

Ironwood, Forest Laboratories announce positive results for linaclotide Phase 3 clinical trials in IBS-C patients

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top-line results from the first of two Phase 3 clinical trials assessing the efficacy and safety of the investigational drug, linaclotide, in patients with irritable bowel syndrome with constipation (IBS-C).

14 Sep 2010

FDA accepts Salix's XIFAXAN550 sNDA for Priority Review

Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Company's efficacy supplement to the New Drug Application (NDA) for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating.

9 Aug 2010

Sucampo Pharmaceuticals second-quarter 2010 total revenue declines to $13.8 million

Sucampo Pharmaceuticals, Inc. today reported its consolidated financial results for the quarter and six months ended June 30, 2010.

7 Aug 2010

Researchers discover manipulation of microRNA-29a shows potential of novel IBS treatment

A possible cause of irritable bowel syndrome has been traced to a small piece of RNA that blocks a substance protecting the colon membrane, leading to hostile conditions that can produce diarrhea, bloating and chronic abdominal pain.New research shows that this RNA segment sends signals that stop the activity of the gene that produces glutamine, an amino acid. Previous research has linked a shortage of glutamine in the gut with the seepage of toxins and bacteria through the intestinal wall, irritating nerves and creating disease symptoms.

3 Aug 2010

Polyethylene glycol "works a bit better" than lactulose for chronic constipation: Study

When ordinary over-the-counter laxatives fail to work, doctors turn to other medications to treat people with constipation. Now, a new review of existing research finds that one common drug treatment is better than another is at helping patients who are desperate to get things moving.

7 Jul 2010

Inquiry into the hospital acquired killer bug starts

A Second World War veteran John Boyle died of Clostridium difficile infection after being admitted to hospital for the first time at the age of 90. He was diagnosed with the infection on January 25 this year and succumbed to it two weeks later. He was one of 18 patients to die at a Scottish hospital when the outbreak of this hospital-acquired infection was reported.

8 Jun 2010

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

Salix Pharmaceuticals, Ltd. today announced that the Company has submitted an efficacy supplement to NDA 21-361 for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating.

8 Jun 2010

Double-balloon endoscopy reveals intestinal lipomas within jejunal duplication cysts

Lipoma of the small intestine is a benign tumor of mesenchymal origin which is mostly found by chance during gastrointestinal investigation. Invaginations account for 2/3 of small bowel occlusion caused by up to 80% of tumors and the lipoma is the most frequent benign tumor that causes invagination in its submucous polypoid and it is in more or less scissile form.

10 May 2010

Targeted antibiotics provide safe, long-lasting improvement for IBS patients, says study

A targeted antibiotic provides effective and long-lasting relief of Irritable Bowel Syndrome symptoms, according to the results of two multisite Phase III clinical trials designed by Cedars-Sinai researchers. Rifaximin is the first drug treatment for IBS that relieves symptoms while it's being administered and continues to benefit patients after they stop taking the drug.

5 May 2010

Ocera Therapeutics presents Phase 2 proof-of-concept study results of AST-120 in non-constipating IBS

Ocera Therapeutics, Inc. presented results yesterday from a Phase 2 proof-of-concept study of AST-120 (spherical carbon adsorbent) in the treatment of patients with non-constipating Irritable Bowel Syndrome (IBS) at DDW, the annual meeting of the American Gastroenterological Association. Data showed that subjects treated with AST-120 responded in a consistent manner with reduction in pain better than placebo at week four and at week eight, the primary time point for analysis. The company plans to initiate a Phase 2b study evaluating AST-120 in non-constipating IBS.

4 May 2010

Growth hormone boosts sprinting capacity in athletes but may have serious side effects

Human Growth Hormone (hGH) has long been used among athletes and body builders for stronger and a more muscular bodies over the past four decades. However it is only now that Sydney-based researchers have published a study that shows that hGH offers no such benefits.

3 May 2010

Women with family history of breast cancer face increase risk of ovarian cancer

Ovarian cancer is the most deadly disease of the female reproductive system, with most cases diagnosed in later stages. Yet while ovarian cancer affects 1 in 70 women in the United States, many women have never discussed the risk with their doctor.

30 Apr 2010

Vidazorb probiotic supplements could minimize severity of IBS symptoms

April is Irritable Bowel Syndrome (IBS) Awareness Month. IBS is a chronic condition affecting between 15 and 20 percent of all adults in the Western world. However, IBS is difficult to identify due to the numerous symptoms associated with it. Almost 40 percent of IBS sufferers report symptoms severe and frequent enough to disrupt their daily lives, making it is a serious issue—one to which Vidazorb® probiotic supplements may offer some relief.

31 Mar 2010

Renowned expert to present latest research on gut microbes at EICC

Trillions and trillions of bacteria live in the human gut. The thought of all these invisible inhabitants inside you might be yucky, but without them we would not be here at all. Which microbes reside in our gut? Are they harmful? Where do they come from? What do they actually do deep in our bowels? Do pre- or pro- biotics affect them?

25 Mar 2010

NIH panel proposes multiple management strategies for lactose intolerant individuals

Lactose intolerance is a real and important clinical syndrome, but quantifying its public health burden is challenging. An NIH Consensus Development panel was convened this week to assess the available evidence on lactose intolerance and health across the age spectrum and across racial and ethnic groups.

25 Feb 2010

Soy products meet nutritional needs of people with lactose intolerance

Today, nutrition experts and physicians who participated in the NIH Consensus Development Conference on Lactose Intolerance and Health released an important report that concluded individuals who ingest inadequate amounts of calcium and vitamin D because of real or perceived lactose intolerance need dietary advice to ensure appropriate intake of missing nutrients.

25 Feb 2010

DNA variations in genes increase risk of developing PI-IBS

Studies of the victims of the Walkerton, Ont. tainted drinking water tragedy have led researchers to discover DNA variations in genes that increase the risk of developing post-infectious irritable bowel syndrome (PI-IBS). The sheer scale of infection and the recording of the health of Walkerton's citizens gave a team of researchers a unique opportunity to study the origin of this disorder.

28 Jan 2010

CCAC doubles its efforts to convince Canadians to prevent colorectal cancer

Following the results of the Angus Reid Strategies and the Applied Health Research Centre at Toronto's St. Michael's Hospital survey conducted on behalf of the Canadian Partnership Against Cancer finding that the majority of Canadians have a good understanding of the benefits of colorectal cancer screening, but are not taking action to get screened, the Colorectal Cancer Association of Canada ("CCAC") is doubling its efforts in 2010 to convince Canadians that they must be more proactive concerning their health and the onset of colorectal cancer.

7 Jan 2010

Montefiore Medical Center first to perform minimally invasive procedure on uterine fibroids

Montefiore Medical Center recently became the only hospital on the East Coast to conduct the Radio Frequency Ablation procedure to shrink uterine fibroids in women 30 years and older.

6 Jan 2010